PRIN: VISION. PNRR 2024 Missione 4, componente 2 Investimento 1.1- Avviso 104/2022 | Characterisation of the role of prometastatic MICAL2 on nuclear envelope and genome integrity through transcriptional control of Lamin A/C.
PNRR, 2022 per la Missione 4, componente 2, investimento 1.3 (PE6) – Heal italia health extended alliance for innovative therapies, advanced lab-research, and integrated approaches of precision medicine Avviso 341/2022 Attivo H43C22000830006 – SPOKE S6
PNRR, 2022 per la Missione 4, componente 2 (CN3) – National Center for Gene Therapy and Drugs based on RNA Technology Avviso 3138/2021 Attivo H43C22000500001
PRIN 2023 PNRR – Missione 4, Componente 2, Investimento 1.1 Sema3A RNA nanodelivery to pancreatic ductal adenocarcinoma microenvironment for the activation of tumor immune response Avviso 341/2022 Attivo H43C22000830006
PNRR, 2022 per la Missione 4, componente 2 Investimento 1.1- Avviso 104/2022 | Nanoformulati innovativi per veicolare l’ossitocina al cervello: potenziale approccio terapeutico per i disturbi del neurosviluppo (NOXY4B)
FET project IN2SIGHT 2022: An in vivo bioengineered chip as a smart intravital multiphoton imaging window for new validation protocols of biomaterials G.A. n.964481
PRIN 2022 – 2022TWRXAW – Functional Role of Protein Folding Intermediates: A Cross-Disciplinary Study Integrating Molecular Simulations with Biophysical and Biochemical Experiments
PRIN 2022 – Scintillating HEterostructures for high Resolution fast PET imAging – SHERPA
Accordo di Cooperazione Industriale, Scientifica e Tecnologica tra Italia e Israele – Track Scientifico 2020.- X–PATH – X-ray activated photodynamic therapy for targeted treatment of Alzheimer disease
FRRB Regione Lombardia 2018. New frontiers of engineered nanovectors to improve treatment efficacy and safety in neurological disorders (NEVERMIND)
Ricerca Finalizzata 2016, Italian Ministery of Health, 2019 – NANOTRACK, Multimodal nanotracking for exosome-based therapy in DMD (2019-2023).
JPND EU project 2015. Development of a Novel Multicellular In Vitro Model of Alzheimer’s disease-like Blood-Brain Barrier (NAB3)